Table 2.

Pathological characteristics and treatment

Pretransplant biopsy (n=41)
HAAS staging
IV	38.8% (n=7)
1V	61.1% (n=34)
MEST score
M1	33.3% (n=6)
E1	5.5% (n=1)
S1	50% (n=9)
T1	44.4% (n=8)
T2	11.1% (n=2)
C1	22.2% (n=4)
C2	11.1% (n=2)
	0%
Posttransplant biopsy (n=51)
HAAS staging
I	17.6% (n=9)
II	11.8% (n=6)
III	25.5% (n=18)
IV	35.3% (n=18)
V	9.8% (n=5)
MEST score
M1	41.2% (n=21)
E1	5.9 (n=3)
S1	49% (n=25)
T1	17.6% (n=9)
T2	0% (n=0)
C1	3.9% (n=2)
C2	0% (n=0)
Proteinuria range
<1 g	15.7% (n=8)
1-3 g	43.1% (n=22)
>3 g	41.2% (n=21)
Treatment
ACE/ARB	100% (n=51)
Omega-3 fatty acids	21.6% (n=11)
High-dose oral steroids	5.9% (n=3)
IV MPS	3.9% (n=2)

HAAS =, MEST=mesangial and endocapillary hypercellularity, segmental sclerosis, and interstitial fibrosis/tubular atrophy, ACE=angiotensin-converting enzyme, ARB=angiotensin II receptor blocker, MPS=mucopolysaccharidosis